Business
Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
- Data showcases sustained clinical benefit following seven years of LIVMARLI treatment in patients with Alagille syndrome - Long-term extension data from
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n- Data showcases sustained clinical benefit following seven years of LIVMARLI treatment in patients with Alagille syndrome\n\n\n- Long-term extension data from LIVMARLI PFIC studies highlight improvement in key liver markers and growth\n\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that data from new analyses showing long-term treatment with LIVMARLI were presented during the European Association for the Study of the Liver (EASL) Annual Congress, June 5-8, 2024, in Milan, Italy. Presentations from studies evaluating LIVMARLI® (maralixibat) oral solution in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) included:\n\n\nTHU-094: Clinical Benefits with Maralixibat for Patients with Alagille Syndrome are Durable Through 7 Years of Treatment: Data from the MERGE Study\nPresented by Doug Mogul, MD, PhD – Mirum Pharmaceuticals, Inc., Foster City, CA, USA\nAn analysis of ALGS studies evaluating LIVMARLI for up to seven years of treatment were presented to demonstrate the durability of response to LIVMARLI across multiple clinical and laboratory outcomes. Data demonstrated that nearly all patients who remained on LIVMARLI for seven years experienced benefit including clinically meaningful reductions in pruritus and serum bile acids, along with improvements in height.\n\n\nView the full presentation.\n\n\nTHU-129: Maralixibat Improves Growth in Patients with Progressive Familial Intrahepatic Cholestasis: Data from the MARCH/MARCH-ON Trials\nPresented by Professor Richard J. Thompson, MD, PhD – King's College, London, UK\nThis analysis reported on the long-term impact of LIVMARLI on improvements in growth across a variety of PFIC types in 60 patients from the All-PFIC cohort of the MARCH/MARCH-ON clinical trials. Patients treated with LIVMARLI from the All-PFIC cohort had a statistically significant improvement in height and weight z-scores which persisted through 82 weeks of treatment.\n\n\nView the full presentation.\n\n\nTHU-158: Improvements in Serum Bile Acid Levels are Associated with Improvements in Key Markers of Liver Health After Maralixibat Treatment in Children with Progressive Familial Intrahepatic Cholestasis: Data from the MARCH/MARCH-ON Trials\nPresented by Lorenzo D’Antiga, MD - Papa Giovanni XXIII Hospital, Bergamo,...